Posts

Posted on

WEX® Launches New WEX Index®, Revealing How the Mobility Fleet Sector Navigated the 2026 Fuel Price Surge

WEX® Launches New WEX Index®, Revealing How the Mobility Fleet Sector Navigated the 2026 Fuel Price Surge

Drawing on proprietary data and experience serving 600,000 mobility customers, the report gives fleet benchmarks for fuel spending, risk, and mixed-energy planning

PORTLAND, Maine–(BUSINESS WIRE)–WEX® (NYSE: WEX), a global leader in intelligent payment solutions, today announced the launch of the WEX Index®: The fleet and mobility spend report. Pairing WEX proprietary transaction data with the company’s expertise, the analysis shows how commercial fleets managed the 2026 fuel price surge, including where and what type of fuel they bought. The report covers January through September 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110226598/en/

The new WEX Index®, built from real transaction data across WEX’s 600,000+ mobility customers, benchmarks fleet fuel spend, fraud risk, and EV readiness to show fleets where they stand and where they may be leaving money on the table.

The new WEX Index®, built from real transaction data across WEX’s 600,000+ mobility customers, benchmarks fleet fuel spend, fraud risk, and EV readiness to show fleets where they stand and where they may be leaving money on the table.

WEX data revealed the average U.S. fuel price rose approximately 43% in the third quarter of 2026 compared to a year earlier, increasing from $3.38 to $4.85 per gallon, while gallons pumped stayed essentially flat. The WEX Index shows that fleets absorbed those costs and kept moving anyway. The report examines purchasing decisions leaders can review, including where drivers fuel and which grade they buy, establishing a baseline for fleets to adapt to the challenges of higher fuel prices.

Key findings from The WEX Index include:

  • Gallons pumped held steady as prices soared. Average U.S. fuel prices rose while gallons purchased remained essentially flat.
  • Some fill-ups cost more than they should. 38.1% of North American commercial fleets paid more than the local WEX Fuel Price Index (FPI) benchmark.
  • Premium fuel is a hidden cost. Analysis shows premium fuel accounts for 7.6% of transactions, at an average cost gap of $0.78 per gallon, representing up to $86.9 million in potential savings for vehicles that don’t require that grade.
  • External threats are growing too. Industry numbers show phishing attacks increased 1,265% since Q4 2022, when generative AI tools became widely available. Additionally, 81.4% of fleets with five or more drivers had at least one driver spending more on fuel than their fleet average, which is a reason for fleets to closely review transactions.
  • EV decisions are best made vehicle by vehicle. In an analysis of 8,798 vehicles, 27% were recommended for EV replacement. As a modeled average, each replacement would save $16,595, or 15% in costs, over the vehicle’s service life.

“Fleets can’t control the price of fuel, but they can control how they respond to it,” said Melissa Smith, chief executive officer and president of WEX. “The WEX Index gives the mobility sector a fixed point of reference built from real transactions by real fleets. With that baseline, fleet managers can see how they compare to their peers, spot risk earlier, and make smarter decisions about everything from fueling habits to building a mixed-energy fleet.”

The WEX Index outlines five practices fleets can use to put the data to work: Set a baseline, compare fueling against the local benchmark, focus on the numbers that matter, assess mixed-energy options, and revisit the baseline as conditions change. It is intended as the first in a series, with future editions comparing against this baseline so fleets can track their own progress against industry figures.

To bring the Index’s findings to a broader business audience, WEX published an article with Bloomberg Media Studios. The piece looks at how fleets are managing a historic fuel price shock with little room to cut consumption, and how choices about where drivers fuel and which grade they buy can uncover savings. Read the article today on Bloomberg.com.

To download the WEX Index, visit www.wexinc.com/resources/wex-index/.

About WEX

WEX (NYSE: WEX) is the global commerce platform that simplifies the business of running a business. WEX has created a powerful ecosystem that offers seamlessly embedded, personalized solutions for its customers around the world. Through its rich data and specialized expertise in simplifying benefits, reimagining mobility, and paying and getting paid, WEX aims to make it easy for companies to overcome complexity and reach their full potential. For more information, please visit www.wexinc.com.

Media Contact:

WEX

Johnston Farrow

832-823-3044

[email protected]

KEYWORDS: Maine United States North America

INDUSTRY KEYWORDS: EV/Electric Vehicles Professional Services Oil/Gas Fleet Management Fintech Payments Energy Technology Autonomous Driving/Vehicles Automotive Trucking Transport Finance

MEDIA:

Photo
Photo
The new WEX Index®, built from real transaction data across WEX’s 600,000+ mobility customers, benchmarks fleet fuel spend, fraud risk, and EV readiness to show fleets where they stand and where they may be leaving money on the table.
Logo
Logo
Posted on

MIND CTI to be Acquired by Enghouse Systems in All-Cash Transaction

MIND CTI Reports
Third
Quarter
2026
Results


Appointment of Orly Sorokin as New CEO

YOQNEAM, Israel, Nov. 10, 2026 (GLOBE NEWSWIRE) — MIND C.T.I. LTD (NasdaqGM:MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product-based solutions for service providers, unified communications (UC) analytics for enterprises as well as enterprise messaging solutions, today announced:

  • The execution of a merger agreement by which Enghouse Systems Ltd. (TSX: ENGH) (“Enghouse”), a leading global provider of enterprise software solutions serving select enterprise vertical markets, will acquire MIND CTI.
  • Its financial results for the third quarter ended September 30, 2026.
  • Appointment of Orly Sorokin as new CEO.

Merger Agreement

Under the terms of the agreement, which has been approved unanimously by the boards of directors of both companies, Enghouse will acquire all outstanding shares of MIND CTI for US$1.30 per share in cash, for a total equity value of approximately US$25.4 million. The purchase price of US$1.30 per share represents a premium of approximately 42% over the weighted average closing price of US$0.92 per share for MIND CTI ordinary shares during the preceding 30 trading days.

Under the merger agreement, a newly formed wholly owned subsidiary of Enghouse will merge with and into MIND CTI, following which MIND CTI will become a wholly owned subsidiary of Enghouse, and each outstanding MIND CTI ordinary share will be exchanged for the right to receive US$1.30 in cash.

The merger is subject to the approval of MIND CTI shareholders and certain customary and other closing conditions. There is no financing condition to the obligations of Enghouse to consummate the transaction. The merger agreement transaction is expected to be closed in the first quarter of 2027.

Monica Iancu has entered into a voting and support agreement with Enghouse, committing to vote all her MIND CTI shares in favor of the merger. This undertaking will terminate if MIND CTI’s board of directors changes its recommendation in favor of the proposed transaction with the current buyers.

Under the terms of the agreement, MIND CTI may actively solicit alternative proposals from third parties until December 10, 2026, and intends to consider any such proposals with the assistance of its independent advisors. MIND CTI does not intend to disclose developments with respect to this solicitation process unless and until its board of directors has made a decision regarding any alternative proposals. There can be no assurance that the solicitation of superior proposals will result in an alternative transaction. In addition, MIND CTI may, at any time, subject to the terms of the merger agreement, respond to unsolicited proposals. If MIND CTI accepts a superior proposal, a break-up fee would be payable by MIND CTI to Enghouse.

Monica Iancu, Interim CEO of MIND, commented: “The MIND CTI Board unanimously approved this transaction because we believe it is in the best interests of our shareholders. Given our size and the increasing costs and burdens associated with being a public company, we see limited benefit in remaining public. This transaction delivers compelling value to our shareholders while positioning the business for continued success.”

Third Quarter Results

The following will summarize our major achievements in the third quarter of 2026, as well as our business. Full financial results can be found in the Company News section of our website at found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K.

Q3
2026
Financial Highlights

  • Revenues were $4.4 million, compared with $4.8 million in the third quarter of 2025.
  • Operating loss was $2.8 million, compared to operating income of $0.6 million in the third quarter of 2025. Our operating loss for the quarter is the result of a non-cash goodwill impairment charge of $3.8 million related to our billing segment.
  • Net loss was $2.9 million, or $0.15 per share, compared to net income of $0.7 million, or $0.03 per share in the third quarter of 2025. Our net loss for the quarter includes the aforesaid non-cash goodwill impairment charge.
  • Cash flow from operating activities was $0.7 million, compared with $1.2 million in the third quarter of 2025.
  • Cash position was $13.7 million as of September 30, 2026.

Nine Months
Financial
Highlights

  • Revenues were $14.1 million, compared with $14.6 million in the first nine months of 2025.
  • Operating loss was $1.2 million, compared to operating income of $1.3 million in the first nine months of 2025. Our operating loss includes the aforesaid non-cash goodwill impairment charge of $3.8 million related to our billing segment.
  • Net loss was $1.2 million, or $0.06 per share, compared to net income of $1.7 million, or $0.08 per share in the first nine months of 2025. Our net loss includes the aforesaid non-cash goodwill impairment charge.
  • Cash flow from operating activities in the first nine months of 2026 was $1.4 million, compared to $2.8 million in the first nine months of 2025.

Revenue Distribution
for
Q
3
2026

Revenues in Europe represented 56% (including the messaging segment revenues in Germany that represented 32%), the Americas represented 34%, and the rest of the world represented 10% of total revenues.

Revenues from our Customer care and billing software were $2.2 million, or 51% of total revenues, enterprise messaging were $1.4 million, or 32% of total revenues, and UC analytics software were $0.8 million, or 17% of total revenues.

Revenues from maintenance and additional services were $4.2 million, or 95% of total revenues, while licenses were $0.2 million, or 5% of total revenues.

Revenue Distribution for
N
ine
M
onths
2026

Revenues in Europe represented 60% (including the messaging segment revenues in Germany that represented 33%), the Americas represented 32%, and the rest of the world represented 8% of total revenues.

Revenues from our Customer care and billing software were $6.9 million, or 49% of total revenues, enterprise messaging were $4.6 million, or 33% of total revenues, and UC analytics software were $2.6 million, or 18% of total revenues.

Revenues from maintenance and additional services were $13.2 million, or 94% of total revenues, while licenses were $0.9 million, or 6% of total revenues.

Buyback Update

As previously announced, MIND’s Board of Directors authorized a new share repurchase plan on November 12, 2025, allowing the Company to repurchase ordinary shares in the open market for up to $2.4 million in cash.

As of September 30, 2026, MIND had purchased a total of 1,038 thousand shares for total consideration of approximately $1,112 thousand, out of which $440 thousand during the third quarter of 2026.

The repurchase program was suspended as of September 22, 2026.

Appointment
of
Orly Sorokin
as
New CEO

The Board of Directors has appointed Ms. Orly Sorokin as Chief Executive Officer, effective November 17, 2026. Ms. Sorokin has served as MIND’s Chief Business Officer since August 2026 and previously served on the Company’s Board of Directors.

Prior to joining MIND as Chief Business Officer, Ms. Sorokin held senior positions at IBM, focusing on sales, emerging technologies and business initiatives. She also held sales and business development positions at MIND from 2000 to 2011.

Ms. Monica Iancu, the Company’s founder, will step down as Interim CEO following the appointment of Orly Sorokin and will continue to serve as Chairperson of the Board of Directors.

Monica Iancu, Chair of the Board of Directors, commented: “We are pleased to announce Orly’s appointment as Chief Executive Officer. Having worked with Orly over the years, I believe her experience, knowledge of the Company and understanding of our industry make her well suited to lead MIND in its next chapter.”

Orly Sorokin commented: “I appreciate the Board’s confidence in appointing me as CEO. MIND has been an important part of my professional career, and I am pleased to have the opportunity to lead the Company. I look forward to taking on this responsibility and working with our team as we move ahead.”

Additional Information and Where to Find It

The merger referenced in this news release has not yet been completed and remains subject to the approval of MIND CTI shareholders and other customary closing conditions. This news release is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell ordinary shares of MIND CTI or any other securities, nor a solicitation of any vote or approval. In connection with the proposed merger, MIND CTI will furnish to the U.S. Securities and Exchange Commission (the “SEC”) a proxy statement on Form 6-K for the extraordinary general meeting of shareholders to be convened to approve the merger.

Shareholders of MIND CTI are advised to read the proxy statement (including the notice of the extraordinary general meeting of shareholders, and related documents), as it may be amended or supplemented from time to time, and any other relevant documents furnished to or filed with the SEC when they become available, before making any decision with respect to the merger because these documents will contain important information about the proposed transaction and the parties thereto.

MIND CTI’s shareholders and other investors can obtain the proxy statement, as it may be amended or supplemented from time to time, and other documents furnished to or filed with the SEC by MIND CTI (when available), for free at the SEC’s website at www.sec.gov. Copies of the documents furnished to or filed with the SEC by MIND CTI also will be available free of charge on MIND CTI’s website at www.mindcti.com or by e-mail at [email protected].

Cautionary Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements”. Forward-looking statements relating to the acquisition of MIND CTI by Enghouse include, but are not limited to, the ability of MIND CTI and Enghouse to complete the transaction contemplated by the Merger Agreement, including the parties’ ability to satisfy the conditions to the consummation of the merger set forth in the Merger Agreement, statements about the expected timing for completing the transaction, the ability to secure approval of MIND CTI’s shareholders, and the potential effects of the acquisition on both Enghouse and MIND CTI. In some cases, forward-looking statements may be identified by terminology such as “believe,” “may,” “will,” “should”, “predict”, “goal”, “strategy”, “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect,” “seek” and similar expressions and variations thereof. These words are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

Forward-looking statements are based on current expectations, beliefs, estimates, projections, and assumptions. As such, forward-looking statements are not guarantees of future performance and involve inherent risks and uncertainties that are difficult to predict. Various factors that could cause actual future results to differ materially from those expressed in forward-looking statements include, but are not limited to, risks associated with uncertainty as to whether the merger transaction will be completed, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, costs and potential litigation associated with the transaction, the failure to obtain shareholder approval, the failure of either party to meet the closing conditions set forth in the merger agreement, risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the proposed transaction, the distraction of management resulting from the proposed transaction, and the risk factors discussed by MIND CTI in its annual report on Form 20-F filed with the SEC for the year ended December 31, 2025, under headings such as “Risk Factors” and “Operating and Financial Review and Prospects.” Except for MIND CTI’s ongoing obligations to disclose material information under the federal securities laws, MIND CTI undertakes no obligation to release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events unless required by law.

About MIND

MIND CTI Ltd. is a leading provider of convergent end-to-end billing and customer care product-based solutions for service providers, unified communications analytics as well as enterprise messaging solutions. MIND provides a complete range of billing applications for any business model (license, SaaS, managed service or complete outsourced billing service) for Wireless, Wireline, Cable, IP Services and Quad-play carriers. A global company, with over twenty-five years of experience in providing solutions to carriers and enterprises, MIND operates from offices in Israel, Romania, Germany and the United States.

For more information please contact:

Janice Kaye
MIND C.T.I. Ltd.
Tel: +972-4-993-6666
[email protected]



Posted on

Hardie, TimberTech & AZEK Selected as Good Housekeeping 2027 Home Reno Awards Winners

Hardie, TimberTech & AZEK Selected as Good Housekeeping 2027 Home Reno Awards Winners

CHICAGO–(BUSINESS WIRE)–
James Hardie announced today that the Hardie TimberHue™ Collection, TimberTech Impression Privacy Screen®, and AZEK Alpine Collection were named winners in Good Housekeeping’s 2027 Home Reno Awards. The full list of awards can be found on goodhousekeeping.com/homereno2027.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110438397/en/

Hardie TimberHue Collection Siding Products - 2027 Good Housekeeping Home Reno Awards

Hardie TimberHue Collection Siding Products – 2027 Good Housekeeping Home Reno Awards

Recognized for their combination of lasting beauty and resilience in demanding climates, the three award-winning products help homeowners, trade professionals and designers create durable, thoughtfully designed spaces built to stand the test of time. James Hardie’s best-in-class portfolio is uniquely represented in Good Housekeeping’s 2027 Home Reno Awards, with three separate brands earning recognition; a distinction no other company shares this year.

Each year, engineers and product analysts at the Good Housekeeping Institute, together with a team of home improvement professionals, spend months rigorously evaluating the best products and services for home remodeling and maintenance. As part of the evaluation process, analysts send products into the homes of consumer testers to see how they perform in real-world conditions, while GH design pros weigh in on style and aesthetics. To determine the winners, judges focus on key attributes including quality, value, efficiency, sustainability, and overall design appeal.

Hardie TimberHue

“Along with its warmth and beauty, the TimberHue Collection meets the same performance standards our engineers have found with other Hardie products that have been through our rigorous evaluation process,” said Dan DiClerico, Home Improvement & Outdoor Lab Director, the Good Housekeeping Institute.

The TimberHue™ Collection of Hardie® products offers new, premium two-toned finishes that combine the timeless beauty of a natural, stained-wood look with the unparalleled durability and performance of Hardie’s renowned fiber cement material and ColorPlus® Technology finishes.

TimberTech Impression Privacy Screen

“Solid construction, including a stabilizing gasket between the rails and slats, eliminates any metal-on-metal rattle, so the screen won’t create a racket of its own as it helps block out noise from the outside world,” added Dan DiClerico.

Impression Privacy Screen is a first-of-its-kind privacy screen solution that provides both decorative screening and functional railing together in one system, offering homeowners a seamless look. An expansion of TimberTech’s existing award-winning railing line, Impression Rail Express®, Impression Privacy Screen is engineered to work together as a unified system and has been wind-load tested for durability so homeowners can have the cohesive look they want with the performance they need.

AZEK Alpine Collection

“Our experts have evaluated AZEK trim in various forms for several years now, enough to verify its resistance to moisture, rot, and insects. We like that the Alpine Collection also maintains a Class A flame spread rating, the highest surface-burning classification available for building materials,” said Dan DiClerico, Home Improvement & Outdoor Lab Director, the Good Housekeeping Institute.

The Alpine™ Collection, features a factory-applied laminate that mimics the look of rich, stained wood. Available in nine natural finishes, Alpine delivers long-lasting beauty for porch ceilings, soffits, and covered walkways—without the maintenance of real wood.

For more information on all James Hardie products, visit jameshardie.com/brands.

About James Hardie Building Products, Inc.

James Hardie Building Products, Inc. is part of the James Hardie group of companies that offer premium exterior and outdoor living solutions through industry-leading brands, including Hardie® siding and trim, TimberTech® decking and railing, AZEK® trim and moulding, and StruXure® pergolas. Together, these brands represent The Home of Resilient Beauty™, helping homeowners and building professionals create beautiful, resilient, low-maintenance home exteriors and outdoor living spaces. James Hardie Building Products, Inc. is a wholly owned subsidiary of James Hardie Industries PLC (NYSE / ASX: JHX).

For more information, visit jameshardie.com/.

Media Contact:

Katie Brockman Co.

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Other Manufacturing Construction & Property Engineering Chemicals/Plastics Landscape Manufacturing Architecture Other Construction & Property Residential Building & Real Estate

MEDIA:

Photo
Photo
Hardie TimberHue Collection Siding Products – 2027 Good Housekeeping Home Reno Awards
Photo
Photo
TimberTech Impression Privacy Screen – 2027 Good Housekeeping Home Reno Awards
Photo
Photo
AZEK Alpine Collection Exterior Products – 2027 Good Housekeeping Home Reno Awards
Logo
Logo
Posted on

Honeywell Technologies Unveils New EBI, Fire and Life Safety and Security Innovations That Bring More Intelligent, Autonomous Operations to Buildings

Honeywell Technologies Unveils New EBI, Fire and Life Safety and Security Innovations That Bring More Intelligent, Autonomous Operations to Buildings

Accelerate 2026 showcases new AI-powered building intelligence via EBI One, as well as the expansion of Honeywell Technologies’ fire and life safety product capabilities for early detection, nuisance alarm reduction and smarter responses

Additional innovations set to be introduced throughout 2027 include a new LenelS2 Adaptive Intelligence Suite for building security and a next-generation Niagara framework

ORLANDO, Fla.–(BUSINESS WIRE)–
Honeywell Technologies (NASDAQ: HON) today introduced a set of new AI-powered building automation offerings, including EBI One, fire and life safety, and security innovations at Accelerate 2026, its largest-ever industry event with more than 2,000 customers and partners. The new technologies are designed to help building owners and operators modernize infrastructure, improve safety and efficiency and accelerate the transition from automation to autonomy with practical, AI-driven features.

“Buildings are at an inflection point with owners and operators being asked to manage increasingly complex environments, often with fewer skilled resources,” said Juan Picon, president and CEO of Honeywell Technologies Building Automation. “Customers today need more than connected systems and volumes of data. Instead, they need technologies that turn information into actionable intelligence, simplify operations and enable better decisions.”

Picon continued, “At Accelerate 2026, we’re demonstrating how Honeywell Technologies is combining decades of building automation expertise with AI and advanced technologies to help customers address these challenges and accelerate the transition to autonomous building operations.”

Honeywell Technologies is introducing several new technologies and expanded capabilities across building operations, fire and life safety and security at Accelerate 2026 and beyond:

  • EBI One brings AI-powered intelligence to building operations. EBI One is a new command and control platform that draws on the AI-powered intelligence of Honeywell Technologies Forge Cognition to continuously assess outcomes and inform operator actions to improve efficiency and safety. Built on Honeywell Technologies’ decades of Enterprise Buildings Integrator (EBI) experience across more than 30,000 buildings, it provides operators with conversational AI operations, intelligent alarm assistance and open integration capabilities designed to simplify operations and help improve safety and efficiency. Click here to view the full release on the launch at Accelerate 2026.
  • New fire and life safety capabilities support earlier detection and smarter response. Honeywell Technologies is introducing low level carbon monoxide (CO) monitoring that provides immediate concentration visibility and trend analysis; System Sensor Distinguishdetector technology that differentiates fire signatures from conditions such as steam, dust and mist to reduce unwanted nuisance alarms; and Incident Command, a software application that brings incident information, unit accountability, operational procedures, and most critically, live data on the evolving conditions within the connected building into a single operational view. Together, these innovations help provide earlier insight into potential risk and developing conditions, reduce nuisance alarms, and improve incident response, helping create safer environments for building occupants and emergency responders. Click here to view the full release on the launch at Accelerate 2026.
  • Expanded AI-powered security capabilities help teams prioritize, manage risk and respond faster. With the upcoming release of LenelS2 Adaptive Intelligence Suite, Honeywell Technologies will bring operatorsAI-weighted alarm management, alarm contextualization, natural-language reporting, unified dashboards, anomaly detection and guided workflows, all designed to reduce alarm fatigue and improve situational awareness. The suite layers contextual AI onto existing platforms, starting with LenelS2 OnGuard to help customers modernize security operations while preserving existing investments. The new suite is expected to be unveiled at ISC West in early 2027.
  • Next generation Niagara framework creates a foundation for increasingly autonomous buildings. Niagara 5, the new generation of the industry-standard Niagara framework, serves as the engine that enables systems from any building or vendor to connect across HVAC, fire, security, access control, lighting and energy. The trusted, open and contextualized view of all building system assets, combined with Forge Cognition intelligence, reduces engineering and commissioning efforts and helps building owners, system integrators and operators accelerate the transition from connected buildings to increasingly autonomous operations. The new Niagara framework is expected to be unveiled at AHR in early 2027.

Together, these innovations demonstrate how Honeywell Technologies combines AI-powered decision support, advanced detection, connected infrastructure and modern building management platforms to help buildings move from automated systems to increasingly autonomous operations.

Honeywell Technologies is already leading the industry transition from automation to autonomy, through Forge Cognition, an agentic AI and simulation platform it recently launched in collaboration with NVIDIA and Dell Technologies. The platform combines real-time digital twins with AI capabilities to help operators understand facility conditions, anticipate issues and coordinate actions across connected systems. In a co-creation deployment at NVIDIA’s headquarters in Santa Clara, Forge Cognition demonstrated an average reduction of 90% in unnecessary alerts, enabling operations teams to focus on what matters most. This co-creation work also identified a potential reduction of up to 10% in energy and utility consumption.

Accelerate 2026 brings this vision to life through executive keynotes, customer-led discussions, hands-on demonstrations and an immersive Innovation Hub showcasing real-world building applications across hospitality, data centers, semiconductors, energy and utilities, commercial buildings, financial services, healthcare, life sciences, government and education.

For more information about Accelerate 2026, visit the event website.

For more information on Honeywell Technologies Building Automation, visit buildings.honeywell.com.

About Honeywell Technologies

Honeywell Technologies is a global, pure-play automation company with a legacy of innovating to help solve the world’s most mission-critical challenges, enhancing the quality of life for people and communities around the world. We serve the building, industrial, and process sectors with a broad portfolio of services, solutions, and products, underpinned by our Honeywell Technologies Accelerator operating system and Honeywell Technologies Forge intelligence layer. By combining the deep domain expertise of our more than 50,000 employees with decades of data from our global installed base, we are uniquely positioned to lead the industrial sector’s transition from automation to autonomy. For more news and information on Honeywell Technologies, please visit Honeywell Technologies Newsroom.

Source: Honeywell Technologies

Media Contact:

Micah Lillard

704-883-6711

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Data Management Technology Construction & Property Building Systems Security Software Artificial Intelligence Networks Mobile/Wireless Hardware Other Construction & Property

MEDIA:

Logo
Logo
Posted on

LULU Investors Have Opportunity to Lead lululemon athletica inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Nov. 10, 2026 (GLOBE NEWSWIRE) — Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against lululemon athletica inc. (“Lululemon” or “the Company”) (NASDAQ: LULU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of LULU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: March 18, 2026 to September 3, 2026

DEADLINE: January 4, 2027

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Lululemon suffered from a drop in store traffic and consumer demand due to negative sentiment and soft new product launches. The Company downplayed the severity of these problems. The Company overstated the strength of its turnaround plan in North America and Mainland China. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Lululemon, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. 

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

 Schall, Brown & Schwartz LLP



Posted on

Intercont (Cayman) Limited Announces Effective Time of Share Consolidation/Reverse Share Split

SINGAPORE, Nov. 10, 2026 (GLOBE NEWSWIRE) — Intercont (Cayman) Limited (“Intercont” or the “Company”), a global shipping enterprise, today announced that it will effect a share consolidation (“Reverse Share Split”) of its ordinary shares at a ratio of 8-for-1, effective as of November 16, 2026 (the “Effective Time”). The company determined that the share consolidation is advisable to mitigate the risk of market manipulation commonly associated with low-priced securities, stabilize the trading profile of our ordinary shares and strengthen the quality of our shareholder base.

Beginning with the opening of trading on November 16, 2026, the Company’s Class A ordinary shares will trade on the Nasdaq Capital Market on a split-adjusted basis, under the same symbol “NCT” but under a new CUSIP number, G48049137.

The Company’s shareholders previously approved the reverse split and granted the Company’s board of directors the authority to determine the final consolidation ration (ranging from 2-for-1 to 1000-for-1) and the timing to for its implementation, provided that such implementation occurs within five years from the date of approval. Upon effecting the consolidation, the number of authorized, issued, and unissued Class A ordinary shares will be reduced proportionally, and the par value per share will be increased by the same ratio. On November 4, 2026, the Company’s board of directors approved the implementation of the Reverse Share Split at the ratio of 8-for-1 as of the Effective Time.

As of the Effective Time, every 8 shares of the Company’s then issued and outstanding Class A ordinary shares will be combined into one issued and outstanding Class A ordinary share without any action on the part of the shareholders. Prior to this current share consolidation, the Company had previously implemented a 25-for-1 share consolidation which became effective on 17 September 2026. Following this current 8-for-1 consolidation, the total number of authorized Class A ordinary shares will be reduced from 3,200,000,000 to 400,000,000, and the par value will change from $0.0625 to $0.50 per Class A share. Meanwhile, the issued Class A ordinary shares will be reduced from 16,286,926 pre-split to 2,035,866 post-split.The authorized Class B ordinary shares will remain unchanged. No fractional Class A Ordinary Shares will be issued in connection with the Reverse Share Split, and any fractional shares of Class A Ordinary Shares resulting from the Reverse Share Split will be rounded up at the beneficial holder level.

The Company’s transfer agent, Transhare Corporation, will serve as the exchange agent for the Reverse Share Split. Registered stockholders holding pre-Reverse Share Split ordinary shares of the Company’s electronically in book-entry form are not required to take any action to receive post- reverse-split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the Reverse Share Split, subject to each brokers’ particular processes, and will not be required to take any action in connection with the Reverse Share Split.

Contact information:
[email protected]
+65 88182399



Posted on

Columbia Threadneedle Investments Launches Two New Laddered Buffer ETFs

Columbia Threadneedle Investments Launches Two New Laddered Buffer ETFs

RECM and RECD expand the firm’s ETF lineup and extend Columbia Threadneedle’s Research Enhanced investment capabilities into a new category of in-demand ETF solutions

BOSTON–(BUSINESS WIRE)–
Columbia Threadneedle Investments today announced the launch of the Columbia RECS Laddered Moderate Buffer ETF (NYSE Arca: RECM) and the Columbia RECS Laddered Deep Buffer ETF (NYSE Arca: RECD), two actively managed ETFs designed to help investors participate in equity market growth while managing downside risk.

The launch of these strategies marks Columbia Threadneedle’s entry into the laddered buffer ETF category and further expands the firm’s growing ETF line-up, offering investors additional ways to access Columbia Threadneedle’s investment capabilities through innovative portfolio solutions. With this launch, Columbia Threadneedle now has 25 ETFs across equities and fixed income with assets under management growing to $13.4 billion1.

RECM and RECD are built upon Columbia Threadneedle’s Research Enhanced Core (RECS) Strategy, which guides the underlying equity portfolios of the new ETFs and serves as the primary source of return potential. Each equity portfolio is paired with put option contracts, time-laddered (or staggered) quarterly in a downside protection strategy designed to reduce the impact of targeted market declines while maintaining meaningful participation in rising markets. Together, the strategies are built for investors seeking equity market upside with less volatility and drawdown potential, helping them remain invested through changing market environments and focused on their long-term financial goals.

“RECM and RECD are designed for investors who want the potential for some equity market upside with less volatility and drawdown,” said Brian Virginia, Head of Insurance Investments and Senior Portfolio Manager at Columbia Threadneedle Investments. “We think of the strategies as combining a strong engine with carefully designed brakes. The underlying equity portfolio seeks to drive long-term growth, while the hedging strategy is designed to reduce the impact of targeted potential market declines. Together, they aim to help investors stay invested and focused on pursuing their long-term goals.”

“RECS is a franchise strategy for Columbia Threadneedle, and we wanted to give clients more ways to put it to work,” said Carlo Forcione, Head of Product Development and Strategy. “With the launch of RECM and RECD, there are now multiple ways to include the exposure in client portfolios, across long-only equity exposure (the RECS ETF), income generation (the RECI ETF3) and now downside protection with moderate buffer (the RECM ETF) and deep buffer (the RECD ETF) approaches. That flexibility allows advisors to align a research-driven core equity portfolio with each client’s goals in mind.”

RECM and RECD reflect the firm’s commitment to offering investors a broad range of investment choices across asset classes, investment styles and risk-management approaches. As investors increasingly seek solutions designed to lower portfolio volatility while maintaining exposure to long-term growth opportunities, the firm believes RECM and RECD represent a valuable addition to the growing buffer ETF category.

Product Overview

Fund Name

Ticker

Fee

Designed For

Portfolio Managers

Columbia RECS Laddered Moderate Buffer ETF

RECM

0.69%

(gross and net)

Investors seeking capital appreciation in a risk-aware manner through volatility reduction in moderate market declines relative to traditional long-only equity strategies.

Brian Virginia

Corey Lorenzen

Chris Lo

Henry Hom

Jason Wang

Columbia RECS Laddered Deep Buffer ETF

RECD

0.69%

(gross and net)

Investors seeking capital appreciation in a risk-aware manner through volatility reduction in deep market declines relative to traditional long-only equity strategies.

Brian Virginia

Corey Lorenzen

Chris Lo

Henry Hom

Jason Wang

For further information on Columbia Threadneedle’s ETF range, please visit https://www.columbiathreadneedleus.com/investment-products/exchange-traded-funds.

About Columbia Threadneedle Investments

Columbia Threadneedle Investments is a leading global asset manager that provides a broad range of investment strategies and solutions for individual, institutional and corporate clients around the world. With more than 2,200 people, including over 550 investment professionals based in North America, Europe and Asia, we manage and advise $743 billion of assets across developed and emerging market equities, fixed income, asset allocation solutions and alternatives.2

Columbia Threadneedle Investments is the global asset management group of Ameriprise Financial, Inc. (NYSE: AMP). For more information, please visit columbiathreadneedleus.com.

Columbia Threadneedle Investments (Columbia Threadneedle) is the global brand name of the Columbia and Threadneedle group of companies.

1 As of September 30, 2026

2 As of September 30, 2026

3 RECI is the NYSE Arca ticker for the Columbia Research Enhanced Core Premium Income ETF

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a free prospectus or a summary prospectus, which contains this and other important information about the funds, visit www.columbiathreadneedleus.com. Read the prospectus carefully before investing.

Columbia Management Investment Advisers, LLC serves as the investment manager to the ETFs. ALPS Distributors, Inc. (Member FINRA) is the distributor for Columbia Threadneedle Investments ETFs. Columbia Management Investment Distributors, Inc., (Member FINRA) is a marketing agent for the ETFs. ALPS Distributors, Inc. is not affiliated with Columbia Threadneedle Investments.

Market risk may affect a single issuer, sector of the economy, industry or the market as a whole. Due to its active management, the Fund could underperform its benchmark index and/or other funds with similar investment objectives and/or strategies. Investing in derivatives is a specialized activity that involves special risks that subject the fund to significant loss potential, including when used as leverage, and may result in greater fluctuation in fund value. The Fund hedges using options linked to the Options Portfolio Index, not the Equity Portfolio itself. To the extent the Equity Portfolio and the Index do not perform similarly, the Fund may not achieve its intended level of downside protection. The Fund uses options to help reduce losses in down markets, but the strategy may not work as intended. The cost of this protection may limit gains when markets rise, and differences between the Fund’s investments and the Options Portfolio Index may reduce its effectiveness. Investors may lose money, including their entire investment. The Fund uses options to help reduce losses in down markets, but the strategy may not work as intended. The cost of this protection may limit gains when markets rise, and differences between the Fund’s investments and the Options Portfolio Index may reduce its effectiveness. The Fund is subject to timing risk meaning that the time at which an investor purchases or sells Fund shares could impact the extent, if any, to which such investor benefits from each Fund’s put option contracts and/or the extent, if any, to which such investor benefits from any appreciation in the Fund’s Equity Portfolio. An investor who purchases Fund shares after the Fund has established option contracts, which the Fund expects to do on a quarterly basis, may have a materially different return profile than an investor who purchased at the time the Fund established its option contracts. If the Fund’s NAV has increased since the applicable option contracts were established, the investor’s ability to participate in upside returns may be reduced or eliminated, and capital protection provided by the Fund’s put options may not begin to benefit that investor until the Fund’s NAV declines substantially further than contemplated at the time the Fund’s options portfolio was established. Conversely, if the Fund’s NAV has declined since the applicable option contracts were established, the investor’s ability to benefit from the capital protection provided by the Fund’s put options may be reduced or eliminated. This product is new with a limited operating history.

Additional Information about Risks of the Fund’s Hedging Strategy. The effectiveness of the Fund’s downside protection strategy depends in large part on the degree to which the performance of the Fund’s Equity Portfolio corresponds with the performance of the Options Portfolio Index. The Equity Portfolio does not seek to track the Options Portfolio Index, but rather the Equity Portfolio Index. Although both the Options Portfolio Index and the Equity Portfolio Index are comprised of U.S. large-cap stocks, the Equity Portfolio Index also includes mid-cap stocks, thus they do not have the same investment exposures and could have different performance results. To the extent the performance of the Equity Portfolio diverges from that of the Options Portfolio Index, the Fund may not achieve the intended level of downside protection, and the downside protection strategy may fail entirely. The sought-after downside protection provided by any single put option contract will not be in effect until the expiration date of the put option contract. Because the Fund ladders its put option contracts, the aggregate level of downside protection at any point in time will reflect the combined effect of multiple put option contracts staggered with different inception dates, strike prices and expiration dates. There can be no guarantee that the Fund will produce upside returns that correlate to increases of the Equity Portfolio Index over time. Additionally, in return for a premium received, the Fund’s sold call option contracts limit the Fund’s participation in gains above the strike price of each sold call option contract, which could have a negative impact on the Fund’s performance relative to the Options Portfolio Index in a market environment where the Options Portfolio Index appreciates beyond the strike price of the sold call option contracts. Over time, the cumulative effect of the Fund’s put/call options strategy (and the downside protection strategy, in general) may cause the Fund to significantly underperform the Equity Portfolio Index, the Options Portfolio Index and similarly situated funds that do not employ a downside protection/hedging overlay, particularly in sustained rising market environments.

AdTrax: CTNA9210352.1-

ALPS: CET003089

Meghan Shields

[email protected]

617.451.0739

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Logitech’s ‘Game Day’ Gives Employees a Dedicated Day Off

Logitech’s ‘Game Day’ Gives Employees a Dedicated Day Off

New Employee Perk Recognizes the Value of Gaming in the Workplace and in Career Development

LAUSANNE, Switzerland & SAN JOSE, Calif.–(BUSINESS WIRE)–
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced Logi Game Day, a dedicated day off for employees to play games while formally recognizing the cognitive and professional benefits of gaming. The initiative marks the first company-wide gaming day in Logitech’s history.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110914936/en/

Logitech’s ‘Game Day’ Gives Employees a Dedicated Day Off

Logitech’s ‘Game Day’ Gives Employees a Dedicated Day Off

Game Day is the natural outcome of Logitech’s research showing a strong link between gaming and professional performance. In the company’s recent Logitech Ctrl Tomorrow study, 81% of gamers believe that gaming builds real-world confidence, reduces anxiety, and correlates with stronger day-to-day work performance. Similarly, another study found that 98.8% of enterprise ITDM respondents reported gaming skills directly translate to workplace capabilities, including strategic thinking, complex problem-solving, and performing under pressure.

“It’s time to retire the stereotype that gaming is a waste of time,” said Hanneke Faber, Logitech’s chief executive officer. “As a company designing products for work and play, we see every day how engagement in one sphere supports performance in the other.”

Getting the Squad Together

Logitech’s gaming brand, Logitech G, announced it will host a streaming event at their Americas headquarters in San Jose to celebrate Game Day on November 19, 2026. Logitech G’s general manager, Robin Piispanen, will host the event.

Piispanen, a former competitive gamer, firmly believes in gaming’s team-building potential. “Whether diving into a game like GTA VI or Call of Duty Modern Warfare 4, shaving seconds off lap times in Forza, or teaming up in an online battle, Game Day gives our team a shared purpose,” he says. “We see firsthand how Logitech employees who sharpen their skills in-game translate directly back to work & problem solving.”

“Play is not the opposite of work,” said Elaine Laird, Logitech’s chief people officer. “When people have dedicated time to log off, decompress and immerse themselves in play, they return with clearer focus, renewed energy and fresh approaches to complex challenges.”

For more information about Logitech and its commitment to workplace culture, visit www.logitech.com. And if you’re interested in joining the Logitech team, visit www.logitech.com/careers.

About Logitech

Logitech creates design-led, software-enabled hardware solutions that help businesses thrive and bring people together when working, creating and gaming in the age of AI. As the point of connection between people and the digital world, our mission is to extend human potential in work and play, in a way that is good for people and the planet. Founded in 1981, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and on the Nasdaq Global Select Market (LOGI). Find Logitech and its other brands, including Logitech G, at www.logitech.com or company blog.

Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A. and/or its affiliates in the U.S. and other countries. All other trademarks are the property of their respective owners. For more information about Logitech and its products, visit the company’s website at www.logitech.com.

Editorial Contacts:

Peter Day – [email protected]

KEYWORDS: Europe Switzerland United States North America California

INDUSTRY KEYWORDS: Entertainment Consumer Electronics Sports eSports Technology Electronic Games Hardware

MEDIA:

Photo
Photo
Logitech’s ‘Game Day’ Gives Employees a Dedicated Day Off
Logo
Logo
Posted on

New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden

New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden

Program launched at American Oncology Network clinics across eight states.

LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana Inc., in collaboration with Evolent Health, Inc. and American Oncology Network (AON), today announced the launch of a new cancer care model designed to improve the quality, timeliness and affordability of cancer care while reducing reliance on traditional prior authorization.

The model has initially been rolled out across eight states to clinics within AON, one of the nation’s fastest-growing community oncology networks.

“We are committed to easing access to quality oncology care for our members and helping to reduce the administrative burden for providers,” said Dr. Traci Granston, Humana Vice President of Clinical Innovation. “A cancer diagnosis is difficult news to hear. By making access to affordable, quality care even easier to navigate and enabling more efficient use of high-cost therapies, we are working to ease the burden of cancer treatment. When members can accelerate the start of cancer treatment, the probability of better health outcomes increases.”

In this model, participating AON providers have a streamlined process for managing most anticancer drug therapies. Practices that demonstrate adherence to established quality and evidence-based treatment standards will no longer need to submit traditional prior authorization requests for those therapies. AON practices are also participating in quality improvement initiatives targeting high-impact opportunities to make care more effective and affordable. As an example, periodic testing of patients receiving immunotherapy can determine whether they are still responding to treatment or if other approaches should be considered. Automated reminders in the AON electronic health record (EHR), in combination with provider education and performance scorecards, aim to increase adoption of these high-value steps. Evolent supports the model through its oncology clinical pathways, quality improvement programs and provider performance reporting.

“We are excited to support Humana members living with cancer through this model,” said Dr. Stephen “Fred” Divers, AON Chief Medical Officer. “Community oncology centers are the lifeblood of the cancer treatment landscape. Through this partnership, we’re bringing them the latest evidence and proven quality interventions to support their treatment decisions, while avoiding the typical friction around approvals that frustrates patients and providers.”

Providers also benefit from a data-driven analytics platform that leverages real-time EHR data to deliver clinical insights and guide the creation of personalized cancer treatment plans. The platform, powered by Meaningful Insights Biotech Analytics (MiBA) and developed in collaboration with AON, applies analytics and algorithms to uncover patterns, trends and correlations that can improve patient care and drive innovation.

“Clinical innovation is not simply about introducing new technology. It is about creating systems and partnerships that make it easier for our care teams to do what is right for patients,” said AON Vice President of Clinical Innovation Susan Sabo-Wagner. “This collaboration represents an opportunity to shift from retrospective approvals toward proactive clinical quality improvement, where physicians and health plans work from trusted clinical information to support timely, appropriate care.”

This new agreement builds on a relationship of more than 20 years between Humana and Evolent, including through Evolent’s New Century Health business, to improve outcomes for members with complex health conditions.

“We’re honored by the trust that Humana has placed in us over the years to support its members in some of their most pivotal health moments,” said Evolent Chief Medical Officer Dr. Von Nguyen. “This new oncology model is emblematic of a partnership that is energized by the opportunity to rethink healthcare and innovate. Together with AON, we’re building a model that reduces reliance on prior authorization by aligning payers and providers around quality and affordability.”

About Humana

Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell® healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

About Evolent

Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in healthcare nationally. Learn more about how Evolent is changing the way healthcare is delivered by visiting evolent.com.

About American Oncology Network

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

Media Contacts:
Humana
Cait Whatley
Humana Corporate Communications
[email protected]

Evolent
Jamie Manfuso
Evolent Media Relations
[email protected]

American Oncology Network
Karen Riley Sawyer
American Oncology Network
[email protected]

KEYWORDS: Kentucky United States North America

INDUSTRY KEYWORDS: Health Insurance Health Oncology

MEDIA:

Logo
Logo
Posted on

Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD

Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD

Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks

Data shared in oral presentation at AASLD The Liver Meeting® and simultaneously published in The New England Journal of Medicine

Results demonstrate how Alnylam’s RNAi platform and strategic partnerships can expand therapeutic opportunities and create long-term value beyond its wholly owned pipeline

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that were sustained through week 36. The Regeneron data were published by The New England Journal of Medicine and simultaneously presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026.

CIDEBsiRNA is an investigational RNAi therapeutic (also known as an siRNA therapeutic). Scientists at the Regeneron Genetics Center® (RGC) analyzed genetic data to discover and/or validate genetic variants in the CIDEB and other genes that are associated with liver disease risk. Building on these findings, Regeneron collaborated with Alnylam to generate an siRNA targeting CIDEB. Since 2023 when the candidate was identified, Regeneron has led development and holds exclusive rights for commercialization of CIDEBsiRNA. Alnylam is eligible to receive development milestones and tiered, double-digit royalties up to 20%.

“The magnitude and durability of the reductions in liver fat observed with CIDEBsiRNA following a single administration are particularly encouraging and represent an important early signal for the potential of RNAi in treating metabolic liver disease,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “These findings reinforce our conviction that RNAi therapeutics can address a much broader range of diseases than those we treat today. They also demonstrate the value of our partnership model, which allows promising science to advance into new disease areas, reach more patients and create additional opportunities for long-term value.”

Regeneron’s ongoing Phase 1/2 randomized, double-blind, placebo-controlled trial is evaluating the safety and tolerability of CIDEBsiRNA in adult participants with MASLD and metabolic dysfunction-associated steatohepatitis (MASH). The primary goal of the trial is to evaluate safety and tolerability with efficacy evaluated as a secondary endpoint through measures such as change in liver fat fraction by magnetic resonance imaging-proton density fat fraction (MRI-PDFF).

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that has become an important and clinically validated platform for drug development. Its discovery was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing RNAi, Alnylam pioneered a new class of medicines known as RNAi therapeutics. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. RNAi therapeutics have been used to treat hundreds of thousands of patients worldwide, demonstrating the impact of this approach across rare and common diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements regarding Alnylam’s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding: the potential efficacy or safety of CIDEBsiRNA for the treatment of MASLD or any other indication; the potential for Alnylam to receive milestones or royalties on account of the development and/or commercialization of CIDEBsiRNA; the potential for RNAi to treat metabolic liver disease and to address a much broader range of diseases than those treated today; the potential for Alnylam’s partnership model to allow Alnylam to allow promising science to advance into new disease areas, reach more patients and create additional opportunities for long-term value; and Alnylam’s ability to achieve the goals in its Alnylam2030 strategy. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s most recent periodic report (Quarterly Report on Form 10-Q or Annual Report on Form 10-K) filed with the SEC and in its other SEC filings. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Alyssa Kneller

(Media)

[email protected]

Josh Brodsky

(Investors)

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo
Logo